Mark Rijpkema1, Wim J Oyen2, Desiree Bos2, Gerben M Franssen2, David M Goldenberg3, Otto C Boerman2. 1. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands mark.rijpkema@radboudumc.nl. 2. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Immunomedics, Inc., Morris Plains, New Jersey; and Center for Molecular Medicine and Immunology, Garden State Cancer Center, Morris Plains, New Jersey.
Abstract
UNLABELLED: Intraoperative visualization techniques promise to significantly improve the detection and resection of tumors. In this study, we used an anti-carcinoembryonic antigen (CEA) antibody (MN-14) tagged with both a radiolabel ((111)In) and a fluorophore (IRDye 800CW) for radionuclide detection and intraoperative fluorescence imaging, respectively. METHODS: For this purpose, we prepared and characterized the dual-labeled antibody (111)In-diethylenetriaminepentaacetic acid (DTPA)-MN-14-IRDye 800CW and performed 4 studies on mice with subcutaneous and intraperitoneal CEA-expressing tumors: a dose escalation study to determine the optimal MN-14 protein dose, a biodistribution study comparing dual-labeled MN-14 and radiolabeled MN-14, a study to determine the optimal time for SPECT and fluorescence imaging after injection of dual-labeled MN-14, and finally a SPECT and fluorescence image-guided surgery study using this dual-labeled antibody. RESULTS: The optimal protein dose of dual-labeled MN-14 was 10 μg per mouse, yielding a tumor-to-blood ratio of 3.5 within 72 h. The biodistribution of (111)In-DTPA-MN-14-IRDye 800CW in mice with subcutaneous LS174T tumors showed tumor uptake after 3 d (19.7% ± 17.0% injected dose/g) comparable to that of (111)In-DTPA-MN-14 but higher accumulation in the liver. The optimal time for imaging after administration of the dual-labeled antibody was 2-3 d after injection. Finally, in mice with intraperitoneally growing LS174T tumor nodules that received (111)In-DTPA-MN-14-IRDye 800CW, intraperitoneal tumor nodules could be localized with SPECT imaging after 3 d and subsequently resected using fluorescence image-guided surgery. CONCLUSION: Thus, we showed the feasibility for assessment and image-guided resection of CEA antigen-expressing tumors using dual-labeled MN-14. Both radionuclide detection and fluorescence imaging may provide useful information to improve localization of tumors and radical excision of tumor tissue. Because humanized MN-14 (labetuzumab) is available for clinical use, translation to a clinical setting is the next step.
UNLABELLED: Intraoperative visualization techniques promise to significantly improve the detection and resection of tumors. In this study, we used an anti-carcinoembryonic antigen (CEA) antibody (MN-14) tagged with both a radiolabel ((111)In) and a fluorophore (IRDye 800CW) for radionuclide detection and intraoperative fluorescence imaging, respectively. METHODS: For this purpose, we prepared and characterized the dual-labeled antibody (111)In-diethylenetriaminepentaacetic acid (DTPA)-MN-14-IRDye 800CW and performed 4 studies on mice with subcutaneous and intraperitoneal CEA-expressing tumors: a dose escalation study to determine the optimal MN-14 protein dose, a biodistribution study comparing dual-labeled MN-14 and radiolabeled MN-14, a study to determine the optimal time for SPECT and fluorescence imaging after injection of dual-labeled MN-14, and finally a SPECT and fluorescence image-guided surgery study using this dual-labeled antibody. RESULTS: The optimal protein dose of dual-labeled MN-14 was 10 μg per mouse, yielding a tumor-to-blood ratio of 3.5 within 72 h. The biodistribution of (111)In-DTPA-MN-14-IRDye 800CW in mice with subcutaneous LS174T tumors showed tumor uptake after 3 d (19.7% ± 17.0% injected dose/g) comparable to that of (111)In-DTPA-MN-14 but higher accumulation in the liver. The optimal time for imaging after administration of the dual-labeled antibody was 2-3 d after injection. Finally, in mice with intraperitoneally growing LS174T tumor nodules that received (111)In-DTPA-MN-14-IRDye 800CW, intraperitoneal tumor nodules could be localized with SPECT imaging after 3 d and subsequently resected using fluorescence image-guided surgery. CONCLUSION: Thus, we showed the feasibility for assessment and image-guided resection of CEA antigen-expressing tumors using dual-labeled MN-14. Both radionuclide detection and fluorescence imaging may provide useful information to improve localization of tumors and radical excision of tumor tissue. Because humanized MN-14 (labetuzumab) is available for clinical use, translation to a clinical setting is the next step.
Authors: Martin C Boonstra; Berend Tolner; Boudewijn E Schaafsma; Leonora S F Boogerd; Hendrica A J M Prevoo; Guarav Bhavsar; Peter J K Kuppen; Cornelis F M Sier; Bert A Bonsing; John V Frangioni; Cornelis J H van de Velde; Kerry A Chester; Alexander L Vahrmeijer Journal: Int J Cancer Date: 2015-06-22 Impact factor: 7.396
Authors: Li Gong; Haiming Ding; Nicholas E Long; Brandon J Sullivan; Edward W Martin; Thomas J Magliery; Michael F Tweedle Journal: Mol Imaging Biol Date: 2018-02 Impact factor: 3.488
Authors: Jan Marie de Gooyer; Fortuné M K Elekonawo; Andreas J A Bremers; Otto C Boerman; Erik H J G Aarntzen; Philip R de Reuver; Iris D Nagtegaal; Mark Rijpkema; Johannes H W de Wilt Journal: Nat Commun Date: 2022-05-12 Impact factor: 17.694
Authors: Martin C Boonstra; Pieter B A A van Driel; Danny M van Willigen; Marieke A Stammes; Hendrica A J M Prevoo; Quirijn R J G Tummers; Andrew P Mazar; Freek J Beekman; Peter J K Kuppen; Cornelis J H van de Velde; Clemens W G M Löwik; John V Frangioni; Fijs W B van Leeuwen; Cornelis F M Sier; Alexander L Vahrmeijer Journal: Oncotarget Date: 2015-06-10
Authors: Reinier Hernandez; Sandra Heskamp; Mark Rijpkema; Desirée L Bos; David M Goldenberg; William J McBride; Alfred Morgenstern; Frank Bruchertseifer; Weibo Cai; Otto C Boerman Journal: Theranostics Date: 2017-01-01 Impact factor: 11.556